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Abstract
Background: Structural changes occur in the pancreas as a part of the natural aging process. With aging, also the
incidence of maldigestive symptoms and malnutrition increases, raising the possibility that these might be caused
at least in part by inadequate pancreatic enzyme secretion due to degenerative processes and damage of the
gland. Fecal elastase-1 is a good marker of pancreatic exocrine secretion. The aim of this study was to investigate
the fecal elastase-1 levels among over 60 years old Finnish and Polish healthy individuals without any special diet,
known gastrointestinal disease, surgery or diabetes mellitus.
Methods: A total of 159 patients participated in this cross-sectional study. 106 older individuals (aged 60-92 years)
were recruited from outpatient clinics and elderly homes. They were divided to three age groups: 60-69 years old
(n = 31); 70-79 years old (n = 38) and over 80 years old (n = 37). 53 young subjects (20-28 years old) were
investigated as controls. Inclusion criteria were age over 60 years, normal status and competence. Exclusion criteria
were any special diet, diabetes mellitus, any known gastrointestinal disease or prior gastrointestinal surgery. Fecal
elastase-1 concentration was measured from stool samples with an ELISA that uses two monoclonal antibodies
against different epitopes of human elastase-1.
Results: Fecal elastase-1 concentrations correlated negatively with age (Pearson r = -0,3531, P < 0.001) and were
significantly lower among subjects over 70 years old compared to controls (controls vs. 70-79 years old and
controls vs. over 80 years old, both P < 0.001). Among the over 60 years old subjects, the fecal elastase-1
concentrations were below the cut off level of 200 μg/g in 23 of 106 (21.7%) individuals [mean 112 (86-138) μg/g]
indicating pancreatic exocrine insufficiency. Of those, 9 subjects had fecal elastase-1 level below 100 μg/g as a
marker of severe pancreatic insufficiency.
Conclusion: In our study one fifth of healthy older individuals without any gastrointestinal disorder, surgery or
diabetes mellitus suffer from pancreatic exocrine insufficiency and might benefit from enzyme supplementation
therapy.
Background
The structural changes occurring in the pancreas as a
part of the natural aging process include patchy fibrosis,
lipomatosis, ductal epithelial hyperplasia, ductal widen-
ing and intraluminal protein deposition which have
been documented in postmortem studies [1-4]. With
aging, also the incidence of maldigestive symptoms and
malnutrition increases, raising the possibility that these
might be caused at least in part by inadequate pancrea-
tic enzyme secretion due to degenerative processes and
damage of the gland.
Only very few previous studies have addressed the effect
of aging on pancreatic exocrine secretion capacity and
those have reported inconsistent results. Gullo et al did
not find any decrease in exocrine pancreatic function mea-
sured by pancreolauryl test in older people (aged 66 to 88
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elastase-1 tests in over 90 years old subjects [6]. In con-
trast, other studies demonstrated that lipase, chymotrypsin
and bicarbonate secretion after secretin and cholecystoki-
nin (CCK) stimulation decreases with age [7] and approxi-
mately 40% reduction in enzyme output was observed in
older people under secretin and cerulein stimulation as
compared with the younger subjects [8]. In an older popu-
lation with a mean age of 58.7 years significantly lower
secretion rates for bicarbonate following secretin and for
the enzymes lipase and amylase following pancreozymin
administration compared to a healthy young population
with a mean age of 31.8 years have been reported [9]. A
large-scale, population based, cohort study evaluated pan-
creatic exocrine secretion in 50 to 75 years old subjects
[10]. In this cohort 11.5% showed signs of exocrine pan-
creatic insufficiency (elastase level < 200 μg/g stool) and
5.1% severe insufficiency (elastase level < 100 μg/g stool).
11.4% of the study population had a history of diabetes
mellitus [10]. These studies suggest that pancreatic
enzyme secretion may be reduced even in normal, healthy
older people with no gastrointestinal diseases due to atro-
phy, fibrosis, sclerosis and lipomatosis of the organ.
Direct tests like the secretin-CCK or secretin-caerulein
test have the highest sensitivity and specificity for the
detection of exocrine pancreatic insufficiency, and they
remain the gold standard for testing pancreatic exocrine
function but they have various practical disadvantages
being time consuming, invasive and expensive. Since
pancreatic elastase-1 is very stable during intestinal tran-
sit and is enriched five- to six fold in feces, it can be
used in the assessment of the pancreatic exocrine secre-
tory capacity [11,12]. Measuring fecal elastase-1 concen-
tration correlates moderately with direct tests [13] and
has several advantages being non-invasive, inexpensive
and allowing sample storage in room temperature up to
five days. Many comparative studies support the value
of fecal elastase-1 test in the assessment of the pancrea-
tic secretion capability. In addition, being species speci-
fic enzyme, human elastase-1 can be differentiated from
the porcine elastase present in enzyme supplements.
The aim of our study was to evaluate the pancreatic
exocrine secretion in older people with no known gas-
trointestinal disease, surgery or diabetes mellitus with a
simple fecal elastase-1 test to estimate the possible need
for exogenous pancreatic enzyme replacement therapy
in the older population.
Methods
Subjects
The study subjects were competent healthy individuals
who were recruited from local elderly homes and health
care centers from Eastern Finland and the ophthalmology
outpatient clinic at the Department of Ophthalmology,
District Hospital, Poznan, Poland. The subjects signed an
informed consent and the study was accepted by the ethi-
cal committee of Hospital district of Northern Savo, Kuo-
pio, Finland and the ethical committee of Poznan
University of Medical Sciences, Poland. All procedures
complied with the Helsinki Declaration.
The inclusion criteria were over 60 years of age, nor-
mal status and competence. Exclusion criteria were any
special diet, alcohol abusers, diabetes mellitus, any
known gastrointestinal disease or prior gastrointestinal
surgery. None of the subjects had been diagnosed with
exocrine pancreatic insufficiency or had been treated
with pancreatic enzymes before the study.
A total of 159 subjects participated in the study. Older
individuals (total n = 106) were divided into three age
groups i) 60-69 years old (n = 31), ii) 70-79 years old
(n = 38), and iii) over 80 years old (n = 37). 53 young
controls (age 20-28 years) served as the control group.
The same selection criteria were applied to controls as
well as to older subjects.
The fecal elastase-1 was measured from 1 g of stool by
an enzyme-linked immunosorbent assay (ScheBo
® Tech,
Giessen, Germany). The test uses two monoclonal anti-
bodies against different epitopes of human elastase-1.
The intra- and inter-assay variations were 5.8% and
7.7%, respectively. Each sample was measured in dupli-
cates. To minimize the intra-individual variation, the
measurement was repeated from three stool samples
from each subject and the average of the three samples
was used for calculation of the results. The cut-off level
for pancreatic insufficiency is elastase-1 concentration
below 200 μg/g stool and for severe pancreatic insuffi-
ciency below 100 μg/g stool.
Statistical analysis
Normal distribution of the data was tested by Kolmo-
gorov-Smirnov test. To compare the elastase-1 levels
between the groups, one-way ANOVA with Tukey’s
multiple comparison test as post test was used. P <0 . 0 5
was considered statistically significant. Correlation was
tested by Pearson test. GraphPad Prism was used for
statistical analysis (GraphPad Software Inc., San Diego,
CA).
Results
Fecal elastase-1 concentration was (means and 95% con-
fidence intervals are given) 570 (518-621) μg/g in con-
trols, 458 (358-558)μg/g in 60-69 years old, 375 (289-
461) μg/g in 70-79 years old and 381 (321-442) μg/g in
over 80 years old subjects (Figure 1). The fecal elastase-
1 concentration was significantly lower in individuals
over 70 years old compared to controls (controls vs. 70-
79 years and controls vs. over 80 years, both P <0 . 0 0 1 ) .
The difference between controls and 60-69 years old
and the differences between the older age groups were
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concentration correlated negatively with age (Pearson r
= -0,3531, P < 0.001, Figure 2). Among the subjects over
60 years old, the fecal elastase-1 concentration was
below the cut off level of 200 μg/g in 23 of 106 (21.7%)
individuals [mean 112 (86-138) μg/g] indicating pan-
creatic exocrine insufficiency. 9 subjects had fecal elas-
tase-1 level below 100 μg/g indicating severe pancreatic
insufficiency. In the control group, one subject had an
elastase-1 level below 200 μg/g.
Discussion
In our investigation we found that 21.7% of subjects
aged over 60 years without any known gastrointestinal
diseases, gastrointestinal surgery or diabetes mellitus
had fecal elastase-1 levels below 200 μg/g indicating
pancreatic exocrine insufficiency. Reduction in exocrine
secretion capacity leads to maldigestion of nutrients
which might manifest as clinical symptoms like malnu-
trition, steatorrhoea, diarrhea, abdominal pain and
weight loss [14]. In addition, as the cause of abdominal
pain remains unclear in about 30% of the cases, pan-
creatic insufficiency should be considered as a possible
etiology in these situations. Our results are comparable
with other studies. Rothenbacher and others included
also diabetics in their large population based study and
found exocrine insufficiency (moderate or severe) in
22.7% and 19% of 65-69 years and 70-75 years old
subjects, respectively [10]. Another study reported elas-
tase-1 levels below 200 μg/g in 18.1% of the nondiabetic
control subjects (mean age 58 years, range 22-80 years)
[15]. In contrast, Gullo et al found that only one of 68
subjects over 90 years old and none in their control
group (mean age 52 years, range 21-81 years) had low
fecal elastase-1 levels [6] and there was no correlation
between fecal elastase-1 and age. The discrepancy might
be explained by tight selection criteria applied by Gullo
and coworkers as their inclusion criteria included nor-
mal nutritional status and lifetime absence of important
diseases, including digestive diseases, diabetes mellitus
and alcohol abuse, suggested weight for height and nor-
mal biochemical examinations of several parameters
possibly leading to exclusion of the cases with pancrea-
tic insufficiency.
Measuring fecal elastase-1 level is the most appropri-
ate indirect test to evaluate pancreatic exocrine function
currently available at the clinics. The sensitivity of fecal
elastase-1 measurement in detecting severe exocrine
insufficiency is excellent (100% in [13,16,17] and 82% in
[18]). In contrast, its sensitivity in mild pancreatic insuf-
ficiency in different studies has been reported to be ran-
ging from 16,7 to 65% [13,16-20]. Some of the studies
have been criticized for their small sample size or for
underestimation of pancreatic insufficiency. However,
considering the modest sensitivity of the test in detect-
ing mild exocrine insufficiency, it should be noted that
the actual prevalence of mild reduction in exocrine
secretion capacity among older people is expected to be
even higher than indicated by fecal elastase-1 measure-
ments. It is well known that the incidence of distur-
bances in the endocrine pancreatic function increases
with age [21] yet the deterioration of the exocrine gland
has gained much less attention. Interestingly, several
studies have reported higher prevalence of impaired
exocrine secretion capacity among diabetic patients than
in nondiabetic controls [15,22-24] although the associa-
tion has not been confirmed by all [10]. Different the-
ories have been proposed why diabetes could impair
exocrine secretion including atrophy of the exocrine
Figure 1 Fecal elastase-1 concentration of subjects in different
age groups with mean values indicated by lines. Controls have
significantly higher elastase-1 levels compared to 70-79 years old or
over 80 years old subjects. The cut off level for pancreatic exocrine
insufficiency of 200 μg/g is marked by a solid line.
Figure 2 Fecal elastase-1 level correlates negatively with age.
Pearson correlation r = - 0.353, P < 0.001.
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of angiopathy, impaired exocrine regulation due to neu-
ropathy or vice versa suggesting that primary exocrine
disease might cause diabetes mellitus [15]. As the patho-
physiology of these events remains unknown, morpholo-
gical studies support the connection between exocrine
and endocrine disease since changes of the pancreas
were observed among diabetics, among those with exo-
crine insufficiency and increasingly so in those patients
with both disorders [25]. In addition to other pathophy-
siological mechanisms, the natural process of aging and
degeneration could affect the endocrine as well as the
exocrine part.
In our study, we evaluated fecal elastase-1 levels in
patients without known diabetes mellitus. The total preva-
lence of diabetes is between 10-20% among 60-79 year old
people and approximately half of these cases are undiag-
nosed [21]. Thus it is likely that our study included also
some subjects with undiagnosed diabetes since we did not
screen them by laboratory tests. The most common causes
of exocrine pancreatic insufficiency are chronic pancreati-
tis and pancreatic surgery followed by other diseases like
cystic fibrosis, acute necrotizing pancreatitis, Shwachman
Diamond syndrome, celiac disease, irritable bowel syn-
drome and inflammatory bowel disease [26-29]. Patients
with any gastrointestinal surgery or known gastrointestinal
disease were excluded from our study but besides the
impact of aging, also underlying undiagnosed diseases
remain as possible etiological factors for reduced fecal
elastase-1 levels. Nevertheless, our study suggests that
among the apparently healthy older subjects without any
known gastrointestinal disease there is a considerable por-
tion of subjects who might benefit from pancreatic enzyme
supplementation therapy. The decline of fecal elastase-1
level below the cut off level 200 μg/g may indicate already
atrophy and degeneration of the gland. However, no corre-
lation was found between fecal elastase-1 levels and clini-
cal symptoms of abdominal discomfort [15]. Clinically
relevant maldigestion may occur earlier than the appear-
ance of overt symptoms [30]. According to present recom-
mendation, every patient with exocrine pancreatic
insufficiency should be treated with pancreatic enzyme
replacement therapy regardless of the amount of steator-
rhoea, maldigestion or clinical symptoms [31].
Conclusions
Among older individuals without any known gastroin-
testinal disease, surgery or diabetes mellitus, one fifth of
the individuals had abnormal fecal elastase-1 levels indi-
cating pancreatic exocrine insufficiency. In the general
unselected population with a high incidence of diabetes
mellitus, malabsorption syndromes and abdominal sur-
gery the incidence might be even higher. It is important
to increase the awareness of these problems in this
population group among general physicians since for
these patients, careful clinical examination and possibly
pancreatic enzyme replacement therapy are warranted.
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